We are an Osaka University spin-out drug discovery startup, co-developing a novel cancer immunotherapy with Osaka University. Our proprietary platform, HVJ-E/IM-0101, converts neutrophils into the anti-tumor N1 phenotype and, through local administration, remodels the systemic tumor microenvironment (TME) toward an anti-tumor state. This enables activation of neutrophils—the most abundant immune cell type—previously difficult to harness with existing approaches. Building on accumulated clinical safety data of IM-0101 and tumor immune amplification via CXCL2 gene delivery, we plan to expand to IM-0102 for lung cancer over the next few years.
A startup overcoming challenges in exosome purification with proprietary high-purity, high-yield technology, offering end-to-end support from research to manufacturing. It accelerates practical applications in drug discovery, contributing to a new foundation for pharmaceutical development and driving medical innovation.
Our core competence is NanoGAS® technology, which enables the long-term stabilization of nano-scale bubbles over several years. In the healthcare sector, we have leveraged this technology to develop a pioneering Fecal Microbiota Transplantation (FMT) technique. Its efficacy and safety have been validated through "Specific Clinical Research" regarding its impact on Autism Spectrum Disorder (ASD). Furthermore, we have established robust clinical evidence, including a 50% reduction in healing time for pressure ulcers and a 50% decrease in the volume of laxatives required for endoscopic procedures. Beyond medicine, NanoGAS® provides superior oxidation inhibition (anti-corrosion) and antibacterial effects. With a proven track record in maintaining the hygiene of humidifiers, our technology is available for licensing and joint development to dramatically enhance the value of products across diverse fields—from healthcare to industrial and HVAC infrastructure.
Millde is a technology-driven company specializing in multi-point Raman spectroscopy and high-sensitivity imaging. It provides non-destructive, label-free analysis of cells, tissues, and materials, primarily through contract research services. Serving regenerative medicine, pharmaceutical, food, and materials industries, Millde delivers high-throughput molecular evaluation. The company also develops and commercializes proprietary multi-point Raman systems and cryogenic Raman technologies, supporting applications from research to industrial implementation.
Aortic stenosis is a life-threatening condition in which the aortic valve becomes severely narrowed. With an aging population, the number of patients is expected to increase dramatically worldwide in the coming years. Although valve replacement has become widely adopted, many patients are either too frail to tolerate the procedure or lack access to specialized treatment centers. As a result, a significant treatment gap still remains. DIVE, the device we are developing, synchronizes balloon expansion with the heartbeat to gently open the narrowed aortic valve. Its key advantage is the minimal physical burden on the patient. Through this technology, we aim to provide a safe and accessible treatment option — and ultimately save as many lives as possible.